| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 96,280 | 76,319 | ||
| Short-term investments | 131,441 | 182,859 | ||
| Accounts receivable | 17,243 | - | ||
| Prepaid expenses and other current assets | 8,582 | 9,408 | ||
| Total current assets | 253,546 | 268,586 | ||
| Right-of-use asset | 4,254 | 4,546 | ||
| Other assets | 14,066 | 8,792 | ||
| Total assets | 271,866 | 281,924 | ||
| Accounts payable | 1,137 | 738 | ||
| Accrued expenses | 16,481 | 15,907 | ||
| Operating lease liabilities, current | 1,404 | 1,399 | ||
| Deferred revenue, current | 4,495 | - | ||
| Total current liabilities | 23,517 | 18,044 | ||
| Operating lease liabilities, net of current portion | 3,055 | 3,367 | ||
| Deferred revenue, net of current portion | 12,041 | - | ||
| Preferred stock-Nonredeemable Preferred Stock | - | 0 | ||
| Total liabilities | 38,613 | 21,411 | ||
| Preferred stock-Series XRedeemable Convertible Preferred Stock | 95,324 | 95,324 | ||
| Common stock, 0.001 par value per share, 150,000,000 shares authorized 56,434,894 and 56,434,219 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 57 | 57 | ||
| Additional paid-in capital | 911,014 | 906,703 | ||
| Accumulated other comprehensive gain | 56 | -16 | ||
| Accumulated deficit | -773,198 | -741,555 | ||
| Total stockholders' equity | 233,253 | 260,513 | ||
| Total liabilities and stockholders' equity | 271,866 | 281,924 | ||
Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. (ATXS)